Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
Ohio State graduate
10.1073/pnas.91.6.2280 75 KajiwaraC.KondoS.UdaS.DaiL.IchiyanagiT.ChibaT.et al (2012)
VX-150 induces analgesia without compromising subject safety in a phase 1 study
This allows the design of linker groups that are sensitive to acidic conditions, such as hydrazone bonds and carbonate esters, which are stable under neutral conditions but can be cleaved under acidic conditions (Fig.8)
This hints that retatrutide could help tackle obesity-related conditions like NAFLD/NASH in addition to weight loss
US$ 23.35
US$ 22.83
US$ 20.65
US$ 22.20
